Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly has chalked ... TRAILBLAZER-ALZ 2 trial, which showed that Kisunla slowed cognitive and functional decline by 35% compared with placebo on the integrated Alzheimer's Disease Rating ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.

with the most planned clinical trials for 2025 are for solid tumours, followed by pain, as per the report. "Eli Lilly targets Scorpion Therapeutics to expand reach in oncology" was originally ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.

Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2 Eli Lillys CEO updates on drug trials amid mixed ...

The Alzheimer’s Association — a Chicago-based nonprofit committed to Alzheimer’s research, care, and support — shared ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...